The study, which Medical Xpress reported on, examined data between 2001 and 2016 from 2,214 privately insured patients who were between 5 and 24 years old.
Researchers found the 1,242 patients who used steroid-sparing therapy were less likely to develop severe complications of Crohn’s disease. Patients who used the therapies were nearly 60 percent less likely to develop perianal fistulas, and the likelihood of surgical intervention for patients who developed fistulas decreased by 55 percent.
Fistulas are a painful complication of Crohn’s, and while most research focuses on treating them when they occur, this study found that steroid-sparing therapy decreased the risk of their formation to begin with.
More articles on surgery centers:
The ‘new normal’ for ASCs: 16 admins on how the pandemic will change the field forever
Dr. Thomas Vikoren: Same-day TJR ‘made all the more important’ by COVID-19
Indiana orthopedic practice with surgery center to open
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
